Skip to main content
Erschienen in: Cancer Microenvironment 1/2010

01.12.2010 | Review Paper

Cancer–Stromal Interactions in Scirrhous Gastric Carcinoma

verfasst von: Masakazu Yashiro, Kosei Hirakawa

Erschienen in: Cancer Microenvironment | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Fibroblasts play an important role in the progression, growth and spread of gastric cancers. Cancer–stroma interactions have been especially evident in the scirrhous type of gastric carcinoma. Fibroblasts are associated with the cancer progression at the primary and metastatic site. The proliferative and invasive ability of scirrhous gastric cancer cells are closely associated with the growth factors produced by organ-specific fibroblasts. Fibroblasts are therefore a key determinant in the malignant progression of gastric cancer and represent an important target for cancer therapies.
Literatur
2.
Zurück zum Zitat Japanese Gastric Cancer A (1998) Japanese classification of gastric carcinoma—2nd English Edition. Gastric Cancer 1(1):10–24CrossRef Japanese Gastric Cancer A (1998) Japanese classification of gastric carcinoma—2nd English Edition. Gastric Cancer 1(1):10–24CrossRef
3.
Zurück zum Zitat Ikeguchi M, Miyake T, Matsunaga T et al (2009) Recent results of therapy for scirrhous gastric cancer. Surg Today 39(4):290–294CrossRefPubMed Ikeguchi M, Miyake T, Matsunaga T et al (2009) Recent results of therapy for scirrhous gastric cancer. Surg Today 39(4):290–294CrossRefPubMed
4.
Zurück zum Zitat Otsuji E, Kuriu Y, Okamoto K et al (2004) Outcome of surgical treatment for patients with scirrhous carcinoma of the stomach. Am J Surg 188(3):327–332CrossRefPubMed Otsuji E, Kuriu Y, Okamoto K et al (2004) Outcome of surgical treatment for patients with scirrhous carcinoma of the stomach. Am J Surg 188(3):327–332CrossRefPubMed
5.
Zurück zum Zitat Tahara E (2004) Genetic pathways of two types of gastric cancer. IARC Sci Publ 157:327–349PubMed Tahara E (2004) Genetic pathways of two types of gastric cancer. IARC Sci Publ 157:327–349PubMed
6.
Zurück zum Zitat Yashiro M, Chung YS, Kubo T et al (1996) Differential responses of scirrhous and well-differentiated gastric cancer cells to orthotopic fibroblasts. Br J Cancer 74(7):1096–1103PubMedCrossRef Yashiro M, Chung YS, Kubo T et al (1996) Differential responses of scirrhous and well-differentiated gastric cancer cells to orthotopic fibroblasts. Br J Cancer 74(7):1096–1103PubMedCrossRef
7.
Zurück zum Zitat Mueller MM, Fusenig NE (2004) Friends or foes—bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 4(11):839–849CrossRefPubMed Mueller MM, Fusenig NE (2004) Friends or foes—bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 4(11):839–849CrossRefPubMed
8.
Zurück zum Zitat Yashiro M, Chung YS, Sowa M (1994) Role of orthotopic fibroblasts in the development of scirrhous gastric carcinoma. Jpn J Cancer Res 85(9):883–886PubMed Yashiro M, Chung YS, Sowa M (1994) Role of orthotopic fibroblasts in the development of scirrhous gastric carcinoma. Jpn J Cancer Res 85(9):883–886PubMed
9.
Zurück zum Zitat Nakazawa K, Yashiro M, Hirakawa K (2003) Keratinocyte growth factor produced by gastric fibroblasts specifically stimulates proliferation of cancer cells from scirrhous gastric carcinoma. Cancer Res 63(24):8848–8852PubMed Nakazawa K, Yashiro M, Hirakawa K (2003) Keratinocyte growth factor produced by gastric fibroblasts specifically stimulates proliferation of cancer cells from scirrhous gastric carcinoma. Cancer Res 63(24):8848–8852PubMed
10.
Zurück zum Zitat Shaoul R, Eliahu L, Sher I et al (2006) Elevated expression of FGF7 protein is common in human gastric diseases. Biochem Biophys Res Commun 350(4):825–833CrossRefPubMed Shaoul R, Eliahu L, Sher I et al (2006) Elevated expression of FGF7 protein is common in human gastric diseases. Biochem Biophys Res Commun 350(4):825–833CrossRefPubMed
11.
Zurück zum Zitat Katoh M, Katoh M (2006) FGF signaling network in the gastrointestinal tract (review). Int J Oncol 29(1):163–168PubMed Katoh M, Katoh M (2006) FGF signaling network in the gastrointestinal tract (review). Int J Oncol 29(1):163–168PubMed
12.
Zurück zum Zitat Katoh M (2008) Cancer genomics and genetics of FGFR2 (Review). Int J Oncol 33(2):233–237PubMed Katoh M (2008) Cancer genomics and genetics of FGFR2 (Review). Int J Oncol 33(2):233–237PubMed
13.
Zurück zum Zitat Takemura S, Yashiro M, Sunami T et al (2004) Novel models for human scirrhous gastric carcinoma in vivo. Cancer science 95(11):893–900CrossRefPubMed Takemura S, Yashiro M, Sunami T et al (2004) Novel models for human scirrhous gastric carcinoma in vivo. Cancer science 95(11):893–900CrossRefPubMed
14.
Zurück zum Zitat Yashiro M, Chung YS, Nishimura S et al (1996) Fibrosis in the peritoneum induced by scirrhous gastric cancer cells may act as “soil” for peritoneal dissemination. Cancer 77(8 Suppl):1668–1675PubMed Yashiro M, Chung YS, Nishimura S et al (1996) Fibrosis in the peritoneum induced by scirrhous gastric cancer cells may act as “soil” for peritoneal dissemination. Cancer 77(8 Suppl):1668–1675PubMed
15.
Zurück zum Zitat Ronnov-Jessen L, Petersen OW, Bissell MJ (1996) Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol Rev 76(1):69–125PubMed Ronnov-Jessen L, Petersen OW, Bissell MJ (1996) Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol Rev 76(1):69–125PubMed
16.
Zurück zum Zitat Tahara E (2008) Abnormal growth factor/cytokine network in gastric cancer. Cancer Microenviron 1(1):85–91CrossRefPubMed Tahara E (2008) Abnormal growth factor/cytokine network in gastric cancer. Cancer Microenviron 1(1):85–91CrossRefPubMed
17.
Zurück zum Zitat Elenbaas B, Weinberg RA (2001) Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp Cell Res 264(1):169–184CrossRefPubMed Elenbaas B, Weinberg RA (2001) Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp Cell Res 264(1):169–184CrossRefPubMed
18.
Zurück zum Zitat Mahara K, Kato J, Terui T et al (1994) Transforming growth factor beta 1 secreted from scirrhous gastric cancer cells is associated with excess collagen deposition in the tissue. Br J Cancer 69(4):777–783PubMedCrossRef Mahara K, Kato J, Terui T et al (1994) Transforming growth factor beta 1 secreted from scirrhous gastric cancer cells is associated with excess collagen deposition in the tissue. Br J Cancer 69(4):777–783PubMedCrossRef
19.
Zurück zum Zitat Yoshida K, Yokozaki H, Niimoto M et al (1989) Expression of TGF-beta and procollagen type I and type III in human gastric carcinomas. Int J Cancer 44(3):394–398CrossRefPubMed Yoshida K, Yokozaki H, Niimoto M et al (1989) Expression of TGF-beta and procollagen type I and type III in human gastric carcinomas. Int J Cancer 44(3):394–398CrossRefPubMed
20.
Zurück zum Zitat Joyce JA, Pollard JW (2009) Microenvironmental regulation of metastasis. Nat Rev Cancer 9(4):239–252CrossRefPubMed Joyce JA, Pollard JW (2009) Microenvironmental regulation of metastasis. Nat Rev Cancer 9(4):239–252CrossRefPubMed
21.
Zurück zum Zitat Cat B, Stuhlmann D, Steinbrenner H et al (2006) Enhancement of tumor invasion depends on transdifferentiation of skin fibroblasts mediated by reactive oxygen species. J Cell Sci 119(Pt 13):2727–2738CrossRefPubMed Cat B, Stuhlmann D, Steinbrenner H et al (2006) Enhancement of tumor invasion depends on transdifferentiation of skin fibroblasts mediated by reactive oxygen species. J Cell Sci 119(Pt 13):2727–2738CrossRefPubMed
22.
Zurück zum Zitat De Wever O, Demetter P, Mareel M et al (2008) Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer 123(10):2229–2238CrossRefPubMed De Wever O, Demetter P, Mareel M et al (2008) Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer 123(10):2229–2238CrossRefPubMed
23.
Zurück zum Zitat De Wever O, Mareel M (2003) Role of tissue stroma in cancer cell invasion. J Pathol 200(4):429–447CrossRefPubMed De Wever O, Mareel M (2003) Role of tissue stroma in cancer cell invasion. J Pathol 200(4):429–447CrossRefPubMed
24.
Zurück zum Zitat Inoue T, Chung YS, Yashiro M et al (1997) Transforming growth factor-beta and hepatocyte growth factor produced by gastric fibroblasts stimulate the invasiveness of scirrhous gastric cancer cells. Jpn J Cancer Res 88(2):152–159PubMed Inoue T, Chung YS, Yashiro M et al (1997) Transforming growth factor-beta and hepatocyte growth factor produced by gastric fibroblasts stimulate the invasiveness of scirrhous gastric cancer cells. Jpn J Cancer Res 88(2):152–159PubMed
25.
Zurück zum Zitat George SJ, Johnson JL, Smith MA et al (2005) Transforming growth factor-beta is activated by plasmin and inhibits smooth muscle cell death in human saphenous vein. J Vasc Res 42(3):247–254CrossRefPubMed George SJ, Johnson JL, Smith MA et al (2005) Transforming growth factor-beta is activated by plasmin and inhibits smooth muscle cell death in human saphenous vein. J Vasc Res 42(3):247–254CrossRefPubMed
26.
Zurück zum Zitat Duffy MJ, Maguire TM, McDermott EW et al (1999) Urokinase plasminogen activator: a prognostic marker in multiple types of cancer. J Surg Oncol 71(2):130–135CrossRefPubMed Duffy MJ, Maguire TM, McDermott EW et al (1999) Urokinase plasminogen activator: a prognostic marker in multiple types of cancer. J Surg Oncol 71(2):130–135CrossRefPubMed
27.
Zurück zum Zitat Herszenyi L, Plebani M, Carraro P et al (2000) Proteases in gastrointestinal neoplastic diseases. Clin Chim Acta 291(2):171–187CrossRefPubMed Herszenyi L, Plebani M, Carraro P et al (2000) Proteases in gastrointestinal neoplastic diseases. Clin Chim Acta 291(2):171–187CrossRefPubMed
28.
Zurück zum Zitat Zeisberg EM, Potenta S, Xie L et al (2007) Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res 67(21):10123–10128CrossRefPubMed Zeisberg EM, Potenta S, Xie L et al (2007) Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res 67(21):10123–10128CrossRefPubMed
29.
Zurück zum Zitat Thiery JP (2002) Epithelial–mesenchymal transitions in tumour progression. Nat Rev Cancer 2(6):442–454CrossRefPubMed Thiery JP (2002) Epithelial–mesenchymal transitions in tumour progression. Nat Rev Cancer 2(6):442–454CrossRefPubMed
30.
Zurück zum Zitat Kalluri R, Neilson EG (2003) Epithelial–mesenchymal transition and its implications for fibrosis. J Clin Invest 112(12):1776–1784PubMed Kalluri R, Neilson EG (2003) Epithelial–mesenchymal transition and its implications for fibrosis. J Clin Invest 112(12):1776–1784PubMed
31.
Zurück zum Zitat Siegel PM, Massague J (2003) Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 3(11):807–821CrossRefPubMed Siegel PM, Massague J (2003) Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 3(11):807–821CrossRefPubMed
32.
Zurück zum Zitat Stetler-Stevenson WG, Aznavoorian S, Liotta LA (1993) Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 9:541–573CrossRefPubMed Stetler-Stevenson WG, Aznavoorian S, Liotta LA (1993) Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 9:541–573CrossRefPubMed
33.
Zurück zum Zitat Boire A, Covic L, Agarwal A et al (2005) PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120(3):303–313CrossRefPubMed Boire A, Covic L, Agarwal A et al (2005) PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120(3):303–313CrossRefPubMed
34.
Zurück zum Zitat Yashiro M, Chung YS, Sowa M (1997) Tranilast (N-(3,4-dimethoxycinnamoyl) anthranilic acid) down-regulates the growth of scirrhous gastric cancer. Anticancer Res 17(2A):895–900PubMed Yashiro M, Chung YS, Sowa M (1997) Tranilast (N-(3,4-dimethoxycinnamoyl) anthranilic acid) down-regulates the growth of scirrhous gastric cancer. Anticancer Res 17(2A):895–900PubMed
35.
Zurück zum Zitat Humar B, Guilford P (2009) Hereditary diffuse gastric cancer: a manifestation of lost cell polarity. Cancer science 100(7):1151–1157CrossRefPubMed Humar B, Guilford P (2009) Hereditary diffuse gastric cancer: a manifestation of lost cell polarity. Cancer science 100(7):1151–1157CrossRefPubMed
36.
Zurück zum Zitat Yashiro M, Nishioka N, Hirakawa K (2006) Decreased expression of the adhesion molecule desmoglein-2 is associated with diffuse-type gastric carcinoma. Eur J Cancer 42(14):2397–2403CrossRefPubMed Yashiro M, Nishioka N, Hirakawa K (2006) Decreased expression of the adhesion molecule desmoglein-2 is associated with diffuse-type gastric carcinoma. Eur J Cancer 42(14):2397–2403CrossRefPubMed
37.
Zurück zum Zitat Nishioka N, Yashiro M, Inoue T et al (2001) A candidate tumor suppressor locus for scirrhous gastric cancer at chromosome 18q 12.2. Int J Oncol 18(2):317–322PubMed Nishioka N, Yashiro M, Inoue T et al (2001) A candidate tumor suppressor locus for scirrhous gastric cancer at chromosome 18q 12.2. Int J Oncol 18(2):317–322PubMed
38.
Zurück zum Zitat Nishimura S, Chung YS, Yashiro M et al (1996) CD44H plays an important role in peritoneal dissemination of scirrhous gastric cancer cells. Jpn J Cancer Res 87(12):1235–1244PubMed Nishimura S, Chung YS, Yashiro M et al (1996) CD44H plays an important role in peritoneal dissemination of scirrhous gastric cancer cells. Jpn J Cancer Res 87(12):1235–1244PubMed
39.
Zurück zum Zitat Koyama T, Yashiro M, Inoue T et al (2000) TGF-beta1 secreted by gastric fibroblasts up-regulates CD44H expression and stimulates the peritoneal metastatic ability of scirrhous gastric cancer cells. Int J Oncol 16(2):355–362PubMed Koyama T, Yashiro M, Inoue T et al (2000) TGF-beta1 secreted by gastric fibroblasts up-regulates CD44H expression and stimulates the peritoneal metastatic ability of scirrhous gastric cancer cells. Int J Oncol 16(2):355–362PubMed
40.
Zurück zum Zitat Nishimura S, Chung YS, Yashiro M et al (1996) Role of alpha 2 beta 1- and alpha 3 beta 1-integrin in the peritoneal implantation of scirrhous gastric carcinoma. Br J Cancer 74(9):1406–1412PubMedCrossRef Nishimura S, Chung YS, Yashiro M et al (1996) Role of alpha 2 beta 1- and alpha 3 beta 1-integrin in the peritoneal implantation of scirrhous gastric carcinoma. Br J Cancer 74(9):1406–1412PubMedCrossRef
41.
Zurück zum Zitat Kizaka-Kondoh S, Itasaka S, Zeng L et al (2009) Selective killing of hypoxia-inducible factor-1-active cells improves survival in a mouse model of invasive and metastatic pancreatic cancer. Clin Cancer Res 15(10):3433–3441CrossRefPubMed Kizaka-Kondoh S, Itasaka S, Zeng L et al (2009) Selective killing of hypoxia-inducible factor-1-active cells improves survival in a mouse model of invasive and metastatic pancreatic cancer. Clin Cancer Res 15(10):3433–3441CrossRefPubMed
42.
Zurück zum Zitat Graf J, Iwamoto Y, Sasaki M et al (1987) Identification of an amino acid sequence in laminin mediating cell attachment, chemotaxis, and receptor binding. Cell 48(6):989–996CrossRefPubMed Graf J, Iwamoto Y, Sasaki M et al (1987) Identification of an amino acid sequence in laminin mediating cell attachment, chemotaxis, and receptor binding. Cell 48(6):989–996CrossRefPubMed
43.
Zurück zum Zitat Akiyama SK, Yamada SS, Chen WT et al (1989) Analysis of fibronectin receptor function with monoclonal antibodies: roles in cell adhesion, migration, matrix assembly, and cytoskeletal organization. J Cell Biol 109(2):863–875CrossRefPubMed Akiyama SK, Yamada SS, Chen WT et al (1989) Analysis of fibronectin receptor function with monoclonal antibodies: roles in cell adhesion, migration, matrix assembly, and cytoskeletal organization. J Cell Biol 109(2):863–875CrossRefPubMed
44.
Zurück zum Zitat Iwamoto Y, Robey FA, Graf J et al (1987) YIGSR, a synthetic laminin pentapeptide, inhibits experimental metastasis formation. Science 238(4830):1132–1134CrossRefPubMed Iwamoto Y, Robey FA, Graf J et al (1987) YIGSR, a synthetic laminin pentapeptide, inhibits experimental metastasis formation. Science 238(4830):1132–1134CrossRefPubMed
45.
Zurück zum Zitat Matsuoka T, Hirakawa K, Chung YS et al (1998) Adhesion polypeptides are useful for the prevention of peritoneal dissemination of gastric cancer. Clin Exp Metastasis 16(4):381–388CrossRefPubMed Matsuoka T, Hirakawa K, Chung YS et al (1998) Adhesion polypeptides are useful for the prevention of peritoneal dissemination of gastric cancer. Clin Exp Metastasis 16(4):381–388CrossRefPubMed
46.
Zurück zum Zitat Yashiro M, Chung YS, Nishimura S et al (1996) Peritoneal metastatic model for human scirrhous gastric carcinoma in nude mice. Clin Exp Metastasis 14(1):43–54CrossRefPubMed Yashiro M, Chung YS, Nishimura S et al (1996) Peritoneal metastatic model for human scirrhous gastric carcinoma in nude mice. Clin Exp Metastasis 14(1):43–54CrossRefPubMed
47.
Zurück zum Zitat Paget S (1989) The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 8(2):98–101PubMed Paget S (1989) The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 8(2):98–101PubMed
48.
Zurück zum Zitat Fidler IJ (2003) The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 3(6):453–458CrossRefPubMed Fidler IJ (2003) The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 3(6):453–458CrossRefPubMed
49.
Zurück zum Zitat Psaila B, Lyden D (2009) The metastatic niche: adapting the foreign soil. Nat Rev Cancer 9(4):285–293CrossRefPubMed Psaila B, Lyden D (2009) The metastatic niche: adapting the foreign soil. Nat Rev Cancer 9(4):285–293CrossRefPubMed
50.
Zurück zum Zitat Nishimura S, Hirakawa-Chung KY, Yashiro M et al (1998) TGF-beta1 produced by gastric cancer cells affects mesothelial cell morphology in peritoneal dissemination. Int J Oncol 12(4):847–851PubMed Nishimura S, Hirakawa-Chung KY, Yashiro M et al (1998) TGF-beta1 produced by gastric cancer cells affects mesothelial cell morphology in peritoneal dissemination. Int J Oncol 12(4):847–851PubMed
51.
Zurück zum Zitat Yashiro M, Chung YS, Inoue T et al (1996) Hepatocyte growth factor (HGF) produced by peritoneal fibroblasts may affect mesothelial cell morphology and promote peritoneal dissemination. Int J Cancer 67(2):289–293CrossRefPubMed Yashiro M, Chung YS, Inoue T et al (1996) Hepatocyte growth factor (HGF) produced by peritoneal fibroblasts may affect mesothelial cell morphology and promote peritoneal dissemination. Int J Cancer 67(2):289–293CrossRefPubMed
52.
Zurück zum Zitat Schor SL, Schor AM, Grey AM et al (1988) Foetal and cancer patient fibroblasts produce an autocrine migration-stimulating factor not made by normal adult cells. J Cell Sci 90(Pt 3):391–399PubMed Schor SL, Schor AM, Grey AM et al (1988) Foetal and cancer patient fibroblasts produce an autocrine migration-stimulating factor not made by normal adult cells. J Cell Sci 90(Pt 3):391–399PubMed
53.
Zurück zum Zitat Durning P, Schor SL, Sellwood RA (1984) Fibroblasts from patients with breast cancer show abnormal migratory behaviour in vitro. Lancet 2(8408):890–892CrossRefPubMed Durning P, Schor SL, Sellwood RA (1984) Fibroblasts from patients with breast cancer show abnormal migratory behaviour in vitro. Lancet 2(8408):890–892CrossRefPubMed
54.
Zurück zum Zitat Olumi AF, Grossfeld GD, Hayward SW et al (1999) Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 59(19):5002–5011PubMed Olumi AF, Grossfeld GD, Hayward SW et al (1999) Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 59(19):5002–5011PubMed
55.
Zurück zum Zitat Lewis MP, Lygoe KA, Nystrom ML et al (2004) Tumour-derived TGF-beta1 modulates myofibroblast differentiation and promotes HGF/SF-dependent invasion of squamous carcinoma cells. Br J Cancer 90(4):822–832CrossRefPubMed Lewis MP, Lygoe KA, Nystrom ML et al (2004) Tumour-derived TGF-beta1 modulates myofibroblast differentiation and promotes HGF/SF-dependent invasion of squamous carcinoma cells. Br J Cancer 90(4):822–832CrossRefPubMed
56.
Zurück zum Zitat Liu Y, Yoshimura K, Yamaguchi N et al (2003) Causation of Borrmann type 4 gastric cancer: heritable factors or environmental factors? Gastric Cancer 6(1):17–23CrossRefPubMed Liu Y, Yoshimura K, Yamaguchi N et al (2003) Causation of Borrmann type 4 gastric cancer: heritable factors or environmental factors? Gastric Cancer 6(1):17–23CrossRefPubMed
57.
Zurück zum Zitat Samel S, Singal A, Becker H et al (2000) Problems with intraoperative hyperthermic peritoneal chemotherapy for advanced gastric cancer. Eur J Surg Oncol 26(3):222–226CrossRefPubMed Samel S, Singal A, Becker H et al (2000) Problems with intraoperative hyperthermic peritoneal chemotherapy for advanced gastric cancer. Eur J Surg Oncol 26(3):222–226CrossRefPubMed
58.
Zurück zum Zitat Prud’homme GJ (2007) Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest 87(11):1077–1091CrossRefPubMed Prud’homme GJ (2007) Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest 87(11):1077–1091CrossRefPubMed
59.
Zurück zum Zitat Murahashi K, Yashiro M, Inoue T et al (1998) Tranilast and cisplatin as an experimental combination therapy for scirrhous gastric cancer. Int J Oncol 13(6):1235–1240PubMed Murahashi K, Yashiro M, Inoue T et al (1998) Tranilast and cisplatin as an experimental combination therapy for scirrhous gastric cancer. Int J Oncol 13(6):1235–1240PubMed
60.
Zurück zum Zitat Yashiro M, Murahashi K, Matsuoka T et al (2003) Tranilast (N-3,4-dimethoxycinamoyl anthranilic acid): a novel inhibitor of invasion-stimulating interaction between gastric cancer cells and orthotopic fibroblasts. Anticancer Res 23(5A):3899–3904PubMed Yashiro M, Murahashi K, Matsuoka T et al (2003) Tranilast (N-3,4-dimethoxycinamoyl anthranilic acid): a novel inhibitor of invasion-stimulating interaction between gastric cancer cells and orthotopic fibroblasts. Anticancer Res 23(5A):3899–3904PubMed
61.
Zurück zum Zitat Iwata C, Kano MR, Komuro A et al (2007) Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via reduction of lymphangiogenesis. Cancer Res 67(21):10181–10189CrossRefPubMed Iwata C, Kano MR, Komuro A et al (2007) Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via reduction of lymphangiogenesis. Cancer Res 67(21):10181–10189CrossRefPubMed
62.
Zurück zum Zitat Tendo M, Yashiro M, Nakazawa K et al (2005) Inhibitory effect of a selective cyclooxygenase inhibitor on the invasion-stimulating activity of orthotopic fibroblasts for scirrhous gastric cancer cells. Cancer science 96(7):451–455CrossRefPubMed Tendo M, Yashiro M, Nakazawa K et al (2005) Inhibitory effect of a selective cyclooxygenase inhibitor on the invasion-stimulating activity of orthotopic fibroblasts for scirrhous gastric cancer cells. Cancer science 96(7):451–455CrossRefPubMed
63.
Zurück zum Zitat Sonoshita M, Takaku K, Oshima M et al (2002) Cyclooxygenase-2 expression in fibroblasts and endothelial cells of intestinal polyps. Cancer Res 62(23):6846–6849PubMed Sonoshita M, Takaku K, Oshima M et al (2002) Cyclooxygenase-2 expression in fibroblasts and endothelial cells of intestinal polyps. Cancer Res 62(23):6846–6849PubMed
64.
Zurück zum Zitat Oshima M, Dinchuk JE, Kargman SL et al (1996) Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87(5):803–809CrossRefPubMed Oshima M, Dinchuk JE, Kargman SL et al (1996) Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87(5):803–809CrossRefPubMed
65.
Zurück zum Zitat Williams CS, Tsujii M, Reese J et al (2000) Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 105(11):1589–1594CrossRefPubMed Williams CS, Tsujii M, Reese J et al (2000) Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 105(11):1589–1594CrossRefPubMed
66.
Zurück zum Zitat Sawaoka H, Kawano S, Tsuji S et al (1998) Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am J Physiol 274(6 Pt 1):G1061–G1067PubMed Sawaoka H, Kawano S, Tsuji S et al (1998) Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am J Physiol 274(6 Pt 1):G1061–G1067PubMed
67.
Zurück zum Zitat Chen WS, Wei SJ, Liu JM et al (2001) Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac. Int J Cancer 91(6):894–899CrossRefPubMed Chen WS, Wei SJ, Liu JM et al (2001) Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac. Int J Cancer 91(6):894–899CrossRefPubMed
68.
Zurück zum Zitat Tsujii M, Kawano S, Tsuji S et al (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93(5):705–716CrossRefPubMed Tsujii M, Kawano S, Tsuji S et al (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93(5):705–716CrossRefPubMed
69.
Zurück zum Zitat Kamei D, Murakami M, Nakatani Y et al (2003) Potential role of microsomal prostaglandin E synthase-1 in tumorigenesis. J Biol Chem 278(21):19396–19405CrossRefPubMed Kamei D, Murakami M, Nakatani Y et al (2003) Potential role of microsomal prostaglandin E synthase-1 in tumorigenesis. J Biol Chem 278(21):19396–19405CrossRefPubMed
70.
Zurück zum Zitat Tendo M, Yashiro M, Nakazawa K et al (2006) A synergic inhibitory-effect of combination with selective cyclooxygenase-2 inhibitor and S-1 on the peritoneal metastasis for scirrhous gastric cancer cells. Cancer Lett 244(2):247–251CrossRefPubMed Tendo M, Yashiro M, Nakazawa K et al (2006) A synergic inhibitory-effect of combination with selective cyclooxygenase-2 inhibitor and S-1 on the peritoneal metastasis for scirrhous gastric cancer cells. Cancer Lett 244(2):247–251CrossRefPubMed
71.
Zurück zum Zitat Yashiro M, Nakazawa K, Tendo M et al (2007) Selective cyclooxygenase-2 inhibitor downregulates the paracrine epithelial–mesenchymal interactions of growth in scirrhous gastric carcinoma. Int J Cancer 120(3):686–693CrossRefPubMed Yashiro M, Nakazawa K, Tendo M et al (2007) Selective cyclooxygenase-2 inhibitor downregulates the paracrine epithelial–mesenchymal interactions of growth in scirrhous gastric carcinoma. Int J Cancer 120(3):686–693CrossRefPubMed
72.
Zurück zum Zitat Hattori Y, Itoh H, Uchino S et al (1996) Immunohistochemical detection of K-sam protein in stomach cancer. Clin Cancer Res 2(8):1373–1381PubMed Hattori Y, Itoh H, Uchino S et al (1996) Immunohistochemical detection of K-sam protein in stomach cancer. Clin Cancer Res 2(8):1373–1381PubMed
73.
Zurück zum Zitat Toyokawa T, Yashiro M, Hirakawa K (2009) Co-expression of keratinocyte growth factor and K-sam is an independent prognostic factor in gastric carcinoma. Oncol Rep 21(4):875–880PubMed Toyokawa T, Yashiro M, Hirakawa K (2009) Co-expression of keratinocyte growth factor and K-sam is an independent prognostic factor in gastric carcinoma. Oncol Rep 21(4):875–880PubMed
74.
Zurück zum Zitat Hattori Y, Odagiri H, Nakatani H et al (1990) K-sam, an amplified gene in stomach cancer, is a member of the heparin-binding growth factor receptor genes. Proc Natl Acad Sci U S A 87(15):5983–5987CrossRefPubMed Hattori Y, Odagiri H, Nakatani H et al (1990) K-sam, an amplified gene in stomach cancer, is a member of the heparin-binding growth factor receptor genes. Proc Natl Acad Sci U S A 87(15):5983–5987CrossRefPubMed
75.
Zurück zum Zitat Katoh M, Hattori Y, Sasaki H et al (1992) K-sam gene encodes secreted as well as transmembrane receptor tyrosine kinase. Proc Natl Acad Sci U S A 89(7):2960–2964CrossRefPubMed Katoh M, Hattori Y, Sasaki H et al (1992) K-sam gene encodes secreted as well as transmembrane receptor tyrosine kinase. Proc Natl Acad Sci U S A 89(7):2960–2964CrossRefPubMed
76.
Zurück zum Zitat Shimizu T, Fujiwara Y, Osawa T et al (2004) Orally active anti-proliferation agents: novel diphenylamine derivatives as FGF-R2 autophosphorylation inhibitors. Bioorg Med Chem Lett 14(4):875–879CrossRefPubMed Shimizu T, Fujiwara Y, Osawa T et al (2004) Orally active anti-proliferation agents: novel diphenylamine derivatives as FGF-R2 autophosphorylation inhibitors. Bioorg Med Chem Lett 14(4):875–879CrossRefPubMed
77.
Zurück zum Zitat Nakamura K, Yashiro M, Matsuoka T et al (2006) A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for Scirrhous gastric cancer. Gastroenterology 131(5):1530–1541CrossRefPubMed Nakamura K, Yashiro M, Matsuoka T et al (2006) A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for Scirrhous gastric cancer. Gastroenterology 131(5):1530–1541CrossRefPubMed
78.
Zurück zum Zitat Yashiro M, Shinto O, Nakamura K et al (2009) Synergistic anti-tumor effects of FGFR2 inhibitor with 5-fluorouracil on scirrhous gastric carcinoma. Int J Cancer 126(4):1004–1016 Yashiro M, Shinto O, Nakamura K et al (2009) Synergistic anti-tumor effects of FGFR2 inhibitor with 5-fluorouracil on scirrhous gastric carcinoma. Int J Cancer 126(4):1004–1016
79.
Zurück zum Zitat Yashiro M, Shinto O, Nakamura K et al (2009) Effects of VEGFR-3 phosphorylation inhibitor on lymph node metastasis in an orthotopic diffuse-type gastric carcinoma model. Br J Cancer 101(7):1100–1106CrossRefPubMed Yashiro M, Shinto O, Nakamura K et al (2009) Effects of VEGFR-3 phosphorylation inhibitor on lymph node metastasis in an orthotopic diffuse-type gastric carcinoma model. Br J Cancer 101(7):1100–1106CrossRefPubMed
80.
Zurück zum Zitat Kawajiri H, Yashiro M, Shinto O et al (2008) A novel transforming growth factor beta receptor kinase inhibitor, A-77, prevents the peritoneal dissemination of scirrhous gastric carcinoma. Clin Cancer Res 14(9):2850–2860CrossRefPubMed Kawajiri H, Yashiro M, Shinto O et al (2008) A novel transforming growth factor beta receptor kinase inhibitor, A-77, prevents the peritoneal dissemination of scirrhous gastric carcinoma. Clin Cancer Res 14(9):2850–2860CrossRefPubMed
81.
Zurück zum Zitat Bierie B, Moses HL (2006) Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 6(7):506–520CrossRefPubMed Bierie B, Moses HL (2006) Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 6(7):506–520CrossRefPubMed
82.
Zurück zum Zitat Akhurst RJ (2002) TGF-beta antagonists: why suppress a tumor suppressor? J Clin Invest 109(12):1533–1536PubMed Akhurst RJ (2002) TGF-beta antagonists: why suppress a tumor suppressor? J Clin Invest 109(12):1533–1536PubMed
Metadaten
Titel
Cancer–Stromal Interactions in Scirrhous Gastric Carcinoma
verfasst von
Masakazu Yashiro
Kosei Hirakawa
Publikationsdatum
01.12.2010
Verlag
Springer Netherlands
Erschienen in
Cancer Microenvironment / Ausgabe 1/2010
Print ISSN: 1875-2292
Elektronische ISSN: 1875-2284
DOI
https://doi.org/10.1007/s12307-010-0036-5

Weitere Artikel der Ausgabe 1/2010

Cancer Microenvironment 1/2010 Zur Ausgabe

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

04.06.2024 Levonorgestrel Nachrichten

Unter Frauen, die ein Levonorgestrel-freisetzendes intrauterines System (IUS) verwenden, ist die Brustkrebsrate um 13% erhöht. Dafür kommt es deutlich seltener zu Endometrium-, Zervix- und Ovarialkarzinomen.

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

03.06.2024 NSCLC Nachrichten

Wie stark Menschen mit fortgeschrittenem NSCLC von einer Therapie mit Immun-Checkpoint-Hemmern profitieren, hängt offenbar auch davon ab, wie sehr die Diagnose ihre psychische Verfassung erschüttert

Antikörper mobilisiert Neutrophile gegen Krebs

03.06.2024 Onkologische Immuntherapie Nachrichten

Ein bispezifischer Antikörper formiert gezielt eine Armee neutrophiler Granulozyten gegen Krebszellen. An den Antikörper gekoppeltes TNF-alpha soll die Zellen zudem tief in solide Tumoren hineinführen.

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.